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Cyclosporine Immunosuppression and Delayed Graft 
Function in 455 Cadaveric Renal Transplants 
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and T.R. Hakala 
SINCE the nephrotoxic properties of cyclo-
sporine A (CyA) were first described, 
there has been concern expressed over the use 
of CyA in non functioning allograft kidneys.] 
Several investigators have reported an 
increased risk of developing delayed graft 
function for CyA-treated kidneys when com-
pared with conventionally treated kidneys.2.3 
At the University of Pittsburgh, we have 
always given CyA preoperatively and have 
continued the regular dosing protocol postop-
eratively regardless of graft function. 4,5 The 
purpose of this study was to review our recent 
results in terms of delayed graft function and 
the relationship of CyA to eventual graft 
outcome. 
METHODS AND MATERIALS 
A retrospective analysis was performed on 455 consec-
utive cadaveric renal transplants done at our institution 
between January 1983 and August 1985. All organs were 
harvested from heart-beating cadavers and stored in ice 
slush until transplanted. Local organ procurement, renal 
transplantions, and postoperative immunosuppressive 
management were performed under our standard guide-
lines,6 Four hundred and thirty-one kidneys were 
obtained locally; 24 were procured for us by other trans-
plant teams as part of our sharing program, and 190 were 
obtained from multiple organ donors (Tables I and 2). 
Delayed graft function (DG F) was defmed as the need 
for dialysis within the first week postoperatively regard-
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less of urinary volume. Permanent nonfunction (PNF) 
was defined as the failure of the kidney to ever regain 
enough function to negate the need for continued dialy-
sis. 
Other than the type of immunosuppression and graft 
results, donor factors evaluated included cold storage 
time, the fate of paired organs, and whether multiple 
organ recovery was involved. Recipient factors evaluated 
included age, cause of renal failure, PRA status prior to 
and at the time of transplant, and primary or retransplant 
status (Table 2). 
Immunosuppression was given preoperatively to all 
patients and consisted of oral, intravenous (IV), or com-
bined CyA and steroids as previously described,6 No 
changes in the standard postoperative CyA dosing were 
made solely on the basis of DGF. High-performance 
liquid chromatography (HPLC) whole blood levels were 
used to aid in dosage adjustment, as was the patients' 
clinical course. 
Statistical analysis of demographic variables was per-
formed using chi square tests. Allograft and patient 
survival rate were calculated using Kaplan-Meier sur-
vival curves. 
RESULTS 
The incidence of DG F for the study popula-
tion was 22% (Table 3), which represented 99 
kidneys, nine of which were lost early to 
technical complications. Sixty-two (63%) of 
the kidneys with DGF eventually regained 
function adequate to replace maintenance 
dialysis, Thirty-seven kidneys (8%), however, 
never regained adequate function and were 
counted as permanent nonfunctioning losses, 
The characteristics of the study popUlation 
were stratified according to the presence or 
absence of DGF, As shown in Table 2, the 
Table 1. Study Population: Cadaveric Renal 
Transplants January 1983 Through August 1985 
Total transplants (renal) 
Locally procured kidneys 
Shared kidneys 
Ice Storage preservation 
455 
431 
24 
455 (100%) 
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Table 2. Recipient Demographics (or) Recipient Population Data Base 
Immediate 
Function 
Diabetic 89/356 (25%) 
Mean age 37.8 
PRA > 30 at transplant 49/356 (13.7%) 
Multiple organ 145/356 (41 %) 
Retransplant 48/356 (13.5%) 
Age >55 yr 34/356 (9.5%) 
incidence of regrafted patients in the DGf 
group was 28% v 13.5% in the early function 
group (P < 0.05). The other significant differ-
ence was in the number of patients older than 
55 in the DG F group. 
The influence of DGF on graft and patient 
survival for primary and regrafted recipients 
is shown in Table 4. The DG F rate for 
primary transplant recipients was 19%, 
including eight technical losses, compared 
with 37% of patients undergoing retransplants 
(P < 0.01). Furthermore, DGF had a signifi-
cant effect on the long-term graft survival 
within each group, the effect being most dele-
Table 3. Incidence of Delayed Graft Function 
on Postoperative Renal Allograft Function 
----
Number Percentage 
Immediate function 356 78 
Delayed graft function' 99 22 
Permanent nonfunctiont 37 89 
'Patients that required hemodialysis within 1 week of 
transplant. 
tNine permanent nonfuctions were due to technical error. 
Delayed 
Graft Function 
16/99 (16%) 
38.5 
18/99 (18%) 
45/99 (45%) 
28/99 (28%) 
18/99 (18%) 
PValue 
NS 
NS 
NS 
<0.05 
<0.05 
terious in retransplant patients where the 
combination resulted in a I-year actuarial 
graft survival of only 32% compared with 62(!t. 
for primary transplants with DG F. The DG F 
rate, however, did not have any impact on 
patient survival which was 96% and 98.6% for 
retransplants and primary transplants, re-
spectively. The permanent non function rate 
(Table 5) for the entire group was 8%; how-
ever, it was 23.6% for retransplant recipients v 
only 5% for primary transplants (P < 0.01). 
To determine whether the detrimental efl'ect 
of DGF was related to the length of preserva-
tion, we looked at the cold storage for each 
group was examined. As shown in Table 6, 
there were no significant differences between 
any of the groups for either the mean cold 
storage time or in the percentage of kidneys 
that were stored for greater than 24 hours. 
The fate of paired kidneys was examined to 
see if donor factors seemed to be more respon-
sible than recipient factors for DG F. There 
were 69 pairs of kidneys that could be fully 
evaluated where either one or both kidneys 
Table 4. Influence of Delayed Graft Function on Patient Survival 
Actuarial Survival 
Grafts 
(%1 
Patient 
Grafts Percentage 1 ma 1 yr (1 yr; %1 
Primary transplants 
Immediate function 308 81 93.5 80 99 
Delayed graft function 71 19 72 62 96 
Total 379 100 89 77 98.6 
Retransplants 
Immediate function 48 63 81 62.5 98 
Delayed graft function 28 37 39 32 93 
Total 76 100 66 51 96 
--------- ~ _ ... --~~-~~ 
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Table 5. Permanent Nonfunction Rate 
Primary transplant 
Retransplant 
Number of 
Kidneys 
19/379 (5%) 
18/76 (23.6%) 
Technical 
Loss 
8 
had DGF (Table 7). In only 27.5% did both 
kidneys experience DGF while in 50 pairs, or 
72.5%, only one kidney had DGF. In this 
latter group, there were no significant differ-
ences between the ages of the recipients or the 
storage times for those kidneys that func-
tioned early and those that experienced DGF. 
DISCUSSION 
The nephrotoxic properties of CyA were 
first reported in clinical studies by Caine et 
aV who recommended that the drug be with-
held until it was determined that the graft was 
functioning to avoid the potentially additive 
effect of a nephrotoxic agent to an already 
compromised renal unit. Some investigators2,3 
have described a significant increase in DG F 
to 40% or 50% (Table 8) in patients pre-
treated with CyA compared with 20% to 30% 
for patients transplanted with conventional 
immunosuppression. They have ascribed this 
difference to CyA nephrotoxicity. However, 
other reports7 12 have failed to document any 
difference in the rate of DGF patients treated 
pre- or postoperatively with CyA and those 
treated with conventional immunosuppression 
including antilymphocyte globulin (ALG). 
Our overall DGF rate of 22% compares favor-
ably with this latter experience and with our 
own historical patients treated with conven-
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tional immunosuppression, \3 thus supporting 
the argument that CyA does not increase the 
rate of DGF. 
Furthermore, studies by ourselves6 and oth-
ers l4 have failed to show any difference in the 
incidence of DGF whether CyA is given oral-
ly, IV, or in combination preoperatively. 
Additionally, Belitsky et al 15 showed that 
there is no difference in the incidence of DGF 
when high (15 mg/kg) loading doses are used 
preoperatively v low (10 mg/kg) loading 
doses. However, a significant prolongation of 
DGF has been demonstrated when IV and 
oral loading were combined,6,14 suggesting 
that the nephrotoxic effect of CyA is less 
likely to cause DG F than to prolong it if it 
occurs. 
The data from this study also support 
recent reports on the detrimental effect of 
delayed graft function on eventual graft sur-
vival regardless of whether conventional 
immunosu ppression 16 or Cy A is used. \0 It fur-
ther supports the finding that regrafted 
patients are more likely to develop DGF with 
significantly worse results than when primary 
recipients develop DGF.12 However, Kramer 
et al reported that the long-term survival of 
the kidneys that developed DGF and were 
treated with CyA was superior in all groups 
when compared with the DGF long-term sur-
vival rates of conventionally treated organs. \0 
Our results compare favorably with the CyA 
results reported by Kramer et al for DG F 
treated kidneys with the exception of 
regrafted patients who developed DGF. For 
this group of patients, the results were the 
Table 6. Donor Factor (Mean Cold Ischemia Time) 
Mean ± SD Stored Over 24 h 
(h) Number Percentage 
Entire group (455) 25 + /- 7 h 218/455 48 
Immediate function (356) 26 +/- 7 h 162/356 4R~R 
DGF (99) 28 +/- 7 h 56/99 56 
Retransplant, DGF (28) 27+/-7h 13/28 46 
Retransplant. immediate (48) 25+/-7h 26/148 54 
Numbers in parentheses denote the number of patients in each group. 
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Table 7. Status of Paired Organs 
Pairs with DGF and DGF 
Pairs with DGF and function 
Total 
Pairs Grafts 
Number Percentage With DGF 
19 
50 
69 
27.5 
72.5 
100 
38 
50 
88 
same as those reported with conventional 
immunosuppression. Patient survival in all 
categories was excellent, once again docu-
menting the relative safety of CyA. 
We conclude that CyA does not increase 
the risk of developing DG F and indeed the 
overall CyA-DGF results are superior to con-
----"""-"--------"-------
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Table 8. Rate of Delayed Graft Function With eyA 
DGF-
Institutions DGF-CyA Conventional P 
Minnesota" 18.7% 11.5% n.s. 
Oxford" 51% 27% p < 0.05 
Birminghamt 34% 40% n.S. 
Brussels" 45% 19% P < 0.05 
"Preoperative CyA. 
tCyA given after diuresis began. 
vention-DG F results. Furthermore, we agree 
with the recommendation of Kramer et al that 
the probability of DGF should not be a deter-
rent to the use of CyA in cadaveric trans-
plants.s 
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